Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment

Novartis will give a solid-tumor-focused cell therapy the T-Charge treatment, after paying $100 million upfront to Legend Biosciences for a selection of CAR-T candidates.